Evidence map›Paper›PMID 39377089›Full record

ArticleERJ open research2024

Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey.

Manuela Funke-Chambour, Philipp Suter, Gisli R Jenkins, Leticia Kawano-Dourado, Christopher J Ryerson, Athol U Wells, Michael Kreuter, Kerri A Johannson, Delphi Survey Participants

Abstract read
In one paragraph

Article in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. [What is certain in the treatment of interstitial lung diseases?]Innere Medizin (Heidelberg, Germany) · 2025
    Review
  4. Article
  5. Article
  6. Editorial: Safety of corticosteroids in respiratory medicine.Frontiers in drug safety and regulation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Manuela Funke-ChambourDepartment for Pulmonology, Allergology and Clinical Immunology, Inselspital, University Hospital Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-3417-5872
Philipp SuterDepartment for Pulmonology, Allergology and Clinical Immunology, Inselspital, University Hospital Bern, Bern, Switzerland.
Gisli R JenkinsMargaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Leticia Kawano-DouradoHcor Research Institute, Hospital do Coracao, Sao Paulo, Brazil and Pulmonary Division, Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil.ORCID https://orcid.org/0000-0003-0784-1331
Christopher J RyersonDepartment of Medicine and Centre of Heart Lung Innovations, University of British Columbia, Vancouver, BC, Canada.
Athol U WellsRoyal Brompton and Harefield NHS Foundation Trust, London, UK.
Michael KreuterMainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany.
Kerri A JohannsonDepartment of Medicine, University of Calgary, Calgary, AB, Canada.
Delphi Survey Participants

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39377089
PMCPMC11456968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.